Literature DB >> 19211503

Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma.

P Bono, H Elfving, T Utriainen, P Osterlund, T Saarto, T Alanko, H Joensuu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19211503     DOI： 10.1093/annonc/mdn729

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  44 in total

Review 1.  Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging.

Authors:  Mohamed Bouattour; Audrey Payancé; Johanna Wassermann
Journal:  World J Hepatol       Date:  2015-09-18

Review 2.  Bevacizumab in advanced NSCLC: chemotherapy partners and duration of use.

Authors:  Ryan D Gentzler; Sarah E Yentz; Jyoti D Patel
Journal:  Curr Treat Options Oncol       Date:  2013-12

Review 3.  Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.

Authors:  Thomas Force; Kyle L Kolaja
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

4.  Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcome.

Authors:  A Wick; N Schäfer; N Dörner; D Schemmer; M Platten; M Bendszus; W Wick
Journal:  J Neurooncol       Date:  2009-08-29       Impact factor: 4.130

Review 5.  Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age.

Authors:  Koji Miyahara; Kazuhiro Nouso; Kazuhide Yamamoto
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

6.  Hypertension and VEGF (Vascular Endothelial Growth Factor) Receptor Tyrosine Kinase Inhibition: Effects on Renal Function.

Authors:  Brian C Boursiquot; Emily C Zabor; Ilya G Glezerman; Edgar A Jaimes
Journal:  Hypertension       Date:  2017-07-24       Impact factor: 10.190

7.  Population pharmacokinetic-pharmacodynamic modelling of 24-h diastolic ambulatory blood pressure changes mediated by axitinib in patients with metastatic renal cell carcinoma.

Authors:  Ying Chen; Brian I Rini; Angel H Bair; Ganesh M Mugundu; Yazdi K Pithavala
Journal:  Clin Pharmacokinet       Date:  2015-04       Impact factor: 6.447

8.  Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.

Authors:  Jennifer J Wheler; Filip Janku; Gerald S Falchook; Tiffiny L Jackson; Siqing Fu; Aung Naing; Apostalia M Tsimberidou; Stacy L Moulder; David S Hong; Hui Yang; Sarina A Piha-Paul; Johnique T Atkins; Guillermo Garcia-Manero; Razelle Kurzrock
Journal:  Cancer Chemother Pharmacol       Date:  2014-01-17       Impact factor: 3.333

9.  Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

Authors:  Suzanne E Dahlberg; Alan B Sandler; Julie R Brahmer; Joan H Schiller; David H Johnson
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

10.  Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies.

Authors:  Herbert I Hurwitz; Pamela S Douglas; John P Middleton; George W Sledge; David H Johnson; David A Reardon; Dafeng Chen; Oliver Rosen
Journal:  Oncologist       Date:  2013-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.